研究者業績

加藤 由布

カトウ ユウ  (yu kato)

基本情報

所属
藤田保健衛生大学 医学部 特別研究員
学位
修士(保建学)(藤田保健衛生大学大学院)

研究者番号
50773412
J-GLOBAL ID
201801005012134614
researchmap会員ID
B000313065

研究キーワード

 3

論文

 6
  • Yamashita C, Moriyama K, Hasegawa D, Kato Y, Sakai T, Kawaji T, Shimomura Y, Kurimoto Y, Nagata M, Nishida O
    Blood purification 46(4) 269-273 2018年7月  査読有り
  • Takahiro Kawaji, Toshikazu Sakai, Kazuhiro Moriyama, Yoshitaka Hara, Tomoyuki Nakamura, Naohide Kuriyama, Yasuyo Shimomura, Yu Kato, Hidefumi Komura, Chizuru Yamashita, Yasuyoshi Kurimoto, Daisuke Hasegawa, Osamu Nishida
    Therapeutic Apheresis and Dialysis 22(3) 290-294 2018年6月1日  査読有り
  • Yasuyo Shimomura, Mika Suga, Naohide Kuriyama, Tomoyuki Nakamura, Toshikazu Sakai, Yu Kato, Yoshitaka Hara, Chizuru Yamashita, Hiroshi Nagasaki, Masao Kaneki, Osamu Nishida
    Journal of Intensive Care 4(1) 48 2016年7月22日  査読有り
  • Yoshitaka Hara, Yasuyo Shimomura, Tomoyuki Nakamura, Naohide Kuriyama, Chizuru Yamashita, Yu Kato, Taku Miyasho, Toshikazu Sakai, Shingo Yamada, Kazuhiro Moriyama, Osamu Nishida
    THERAPEUTIC APHERESIS AND DIALYSIS 19(4) 308-315 2015年8月  査読有り
  • 西田修, 湯本美穂, 森山和広, 加藤由布, 下村泰代, 中村智之, 栗山英直, 原嘉孝, 伊藤舞, 野田昌宏, 秋山正慶, 早川聖子, 小松聖史, 山田晋吾, 宮庄拓
    日本アフェレシス学会雑誌 31(2) 148-155 2012年5月31日  
  • 西田 修, 湯本 美穂, 森山 和広, 加藤 由布, 下村 泰代, 中村 智之, 栗山 英直, 原 嘉孝, 伊藤 舞, 野田 昌宏, 秋山 正慶, 早川 聖子, 小松 聖史, 山田 晋吾, 宮庄 拓
    日本アフェレシス学会雑誌 31(2) 148-155 2012年  
    The high mobility group box 1 protein (HMGB1) is an alarmin that plays an important role in sepsis and has been recognized as a promising target with a wide therapeutic window ; however, no drugs or devices are currently in practical use. Here we demonstrate the removal capacity of HMGB1 using seven internationally available membranes in vitro. High cut-off (HCO) membrane showed lower clearance than the adsorbing-membranes such as PMMA and AN69ST. AN69ST showed the dramatically high adsorption clearance of 60 mL/min in dealing with 100 mL/min of test solution flow. Similar results were obtained in the case of plasma. Moreover, no saturation of HMGB1 on AN69ST was observed. For the treatment of septic shock, we have selected the high-volume, high flow modality using 2.1 m^2 PMMA dialyser, with sustained high-efficiency daily diafiltration using a mediator-adsorbing membrane (SHEDD-fA), for breaking the vicious cycle of mediators. In our study, subjects were enrolled as septic shock patients and most patients were in septic shock without renal failure. We demonstrated the effectiveness for septic shock and amazingly high clearance of HMGB1, IL-6. IL-8 and IL-10. Adsorption is a promising mechanism to remove large-molecular-weight cytokines such as HMGB1 effectively.

講演・口頭発表等

 40

共同研究・競争的資金等の研究課題

 1